Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas

American Journal of Physiology - Endocrinology and Metabolism

Volumn 280, Issue 3 43-3, 2001, Pages

  Silvestre, R A ^a   Rodriguez Gallardo J ^a   Jodka, C ^b   Parkes, D G ^b   Pittner, R A ^b   Young, A A ^b   Marco, J ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Amylin; Glucagon; In vivo; Isolated islets; Rat pancreas

Indexed keywords

AMYLIN; ARGININE; CARBACHOL; GLUCAGON; SOMATOSTATIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; IN VIVO STUDY; ISOLATED ORGAN; NONHUMAN; PANCREAS ISLET BETA CELL; PATCH CLAMP; PRIORITY JOURNAL; RAT;

EID: 0343831910     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.2001.280.3.e443     Document Type: Article

References (36)

1. Beaumont K, Gedulin B, Jodka C, Lawler R, and Young A. Concentration-response for glucagonostatic effect of pramlintide in rats (Abstract). Diabetologia 41: A168, 1998.
2. Bennet WM, Beis CS, Ghatei MA, Byfield PGH, and Bloom SR. Amylin tonally regulates arginine-stimulated insulin secretion in rats. Diabetologia 37: 436-438, 1994.
3. Dégano P, Silvestre RA, Salas M, Peiró E, and Marco J. Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas. Regul Pept 43: 91-96, 1993.
4. Faloona GR and Unger R. Glucagon. In: Methods of Hormone Radloimmunoassay, edited by Jaffe BM and Behrman HR. New York: Academic, 1974, p. 317-330.
5. Gedulin B, Jodka C, and Young A. Pramlintide inhibits arginine-induced glucagon secretion in rats (Abstract). Diabet Med 14: S26, 1997.
6. Gedulin B, Percy A, Jodka C, and Young A. Endogenous amylin inhibits glucagon secretion, as demonstrated by studies using neutralizing antibody and the antagonist AC187 (Abstract). Diabet Med 14: S18, 1997.
7. Gedulin BR, Rink TJ, and Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46: 67-70, 1997.
8. Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Karam JH, and Forsham PH. Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med 292: 985-989, 1975.
9. Gerich JE, Tsalikian E, Lorenzi M, Schneider V, Bohannon NV, Gustafson G, and Karam JH. Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin. J Clin Endocrinol Metab 41: 1178-1180, 1975.
10. Havel PJ and Ahrén B. Activation of autonomie nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. Diabetes 46: 801-807, 1997.
11. Kogire M, Ishizuka J, Thompson JC, and Greeley GH. Inhibitory action of islet amyloid polypeptide and calcitonin gene-related peptide on release of insulin from the isolated perfused rat pancreas. Pancreas 6: 459-463, 1991.
12. Kostianovsky M, Lacy PE, Greider MH, and Still MF. Long term (15 days) incubation of islets of Langerhans isolated from adult rats and mice. Lab Invest 27: 53-61, 1972.
13. Lakey JR, Warnock GL, Ao Z, and Rajotte RV. Bulk cryopreservation of isolated islets of Langerhans. Cell Transplant 5: 395-404, 1996.
14. Leclercq-Meyer V, Marchand J, Leclercq R, and Malaisse WJ. Glucagon and insulin release by the in vitro perfused rat pancreas. Diabetes Metab 2: 57-65, 1976.
15. Lehman-deGaeta LS, Willis AC, Young AA, Foot EA, Albrecht E, Leighton B, Rink TJ, and Cooper GJS. Variability of chemically synthesized human amylin (Abstract). Diabetes 40: 236A, 1991.
16. Lindsey CA, Faloona GR, and Unger RH. Plasma glucagon levels during rapid exsanguination with and without adrenergic blockade. Diabetes 24: 313-316, 1975.
17. Müller WA, Faloona GR, Aguilar-Parada E, and Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283: 109-115, 1970.
18. Nyholm B, Orskov L, Hove KY, Gravholt CH, Moller N, Alberti KG, Moyses C, Kolterman O, and Schmitz O. The amylin analog pramlintide improves glycemic control and rduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48: 935-941, 1999.
19. Ogawa A, Harris V, McCorkle SK, Unger RH, and Luskey KL. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 85: 973-976, 1990.
20. Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H, and Yoshida S. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 160: 961-967, 1989.
21. Panagiotidis G, Salehi AA, Westermark P, and Lundquist I. Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse. Diabetes Res Clin Pract 18: 167-171, 1992.
22. Parkes D, Chen K, Smith P, and Young A. Amylin does not suppress hypoglycemia-induced secretion of glucagon in rats (Abstract). Diabetes 48: A425, 1999.
23. Peiró E, Dégano P, Silvestre RA, and Marco J. Inhibition of insulin release by amylin is not mediated by changes in somatostatin output. Life Sci 49: 761-765, 1991.
24. Percy AJ, Trainor DA, Rittenhouse J, Phelps J, and Koda JE. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 42: 576-585, 1996.
25. Riediger T, Rauch M, Jurat G, and Schmid HA. Central nervous targets for pancreatic amylin (Abstract). Pflügers Arch Eur J Physiol Suppl 437: R142, 1999.
26. Salas M, Silvestre RA, Garcia-Hermida O, Fontela T, Rodriguez-Gallardo J, and Marco J. Inhibitory effect of amylin (islet amyloid polypeptide) on insulin response to non-glucose stimuli: study in perfused rat pancreas. Diabetes Metab 21: 269-273, 1995.
27. Siegel S and Castellan NJ. Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill, 1988.
28. Silvestre RA, Miralles P, Moreno P, Villanueva ML, and Marco J. Somatostatin, insulin and glucagon secretion by the perfused pancreas from the cysteamine-treated rat. Biochem Biophys Res Commun 134: 1291-1297, 1986.
29. Silvestre RA, Peiró E, Dégano P, Miralles P, and Marco J. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 31: 23-31, 1990.
30. Silvestre RA, Rodríguez-Gallardo J, Gutiérrez E, García P, Egido EM, and Marco J. Failure of amylin to directly affect glucagon release. Study in the perfused rat pancreas (Abstract). Diabetologia 42: A146, 1999.
31. Silvestre RA, Rodríguez-Gallardo J, Gutiérrez E, and Marco J. Influence of glucose concentration on the inhibitory effect of amylin on insulin secretion: study in the perfused rat pancreas. Regul Pept 68: 31-35, 1997.
32. Wang F, Adrian TE, Westermark GT, Ding XZ, Gasslander T, and Permert J. Islet amyloid polypeptide tonally inhibits β-, α-, and δ-cell secretion in isolated rat pancreatic islets. Am J Physiol Endocrinol Metab 276: E19-E24, 1999.
33. Wang Z-L, Bennet WM, Ghatei MA, Byfield PGH, Smith DM, and Bloom SR. Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 42: 330-335, 1993.
34. Young A, Moore C, Herich J, and Beaumont K. Neuroendocrine actions of amylin. In: Calcitonin Gene-Related Peptide (CGRP), edited by Poyner D, Marshall I, and Brain S. Austin, TX: Landes, 1999, chapt. 9, p. 91-102.
35. Young AA, Rink TJ, and Wang MW. Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP-alpha) in the fasted, anaesthetized rat. Life Sci 52: 1717-1726, 1993.
36. Young AA, Wang MW, and Cooper GJS. Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett 291: 101-104, 1991.